News and Comments

ARRAY Rallies On Successful NEMO trial Results Of Binetinib on NRAS-Mutant Melanoma

  Wednesday, December 16, 2015

When you do your due diligence, you do not lose your faith in what you believed in giving up to the hype that’s sprayed around you. We were happy today to hear Array BioPharma (ARRY) report that results from the Phase 3 NEMO clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma. The trial met its primary endpoints.  More...

Halozyme PEGPH20 Improves the Efficacy of Halavan In Triple Negative Breast Cancer

  Thursday, December 10, 2015

Halozyme Therapeutics (HALO) and Eisai Inc. presented a scientific poster entitled, "Pegylated Recombinant Human Hyaluronidase PH20 (PEGPH20) Enhances Efficacy of Eribulin Mesylate (HALAVEN®) in Triple Negative Breast Cancer Xenografts" at the 38th Annual San Antonio Breast Cancer Symposium (SABCS).   More...

XOMA: Good News for the Firm We Love and Hate But We Never Divorce

  Wednesday, December 02, 2015

XOMA Announces License Agreement with Novo Nordisk for XMetA Program in Diabetes  More...

BIOMARIN: What Happened During the FDA Committee Meeting?

  Wednesday, November 25, 2015

 More...

Biomarin: The DMD Drug and the FDA Committee Options

  Tuesday, November 24, 2015

Today, the FDA advisory panel will discuss BioMarin (BMRN) product drisapersen for Duchenne muscular dystrophy based on documents released to the committee by the FDA. The FDA said, “The benefit of drisapersen in exon 51 skip amenable patients is inconclusive at this time. Therefore, the benefit-risk assessments were not made.”  More...

VERTEX: Orkambi Approved In Europe. What Vertex is Doing to Further improve CF Treatments

  Friday, November 20, 2015

Europe Approves Orkambi®  More...

Ziopharm Wages Its Own War On Brain Cancer

  Thursday, November 19, 2015

When we hear about a new approach that promises bringing in hopefulness in patients diagnosed with brain glioma, we try to listen and hope for the best, rather than develop and demonstrate  skepticism. Are we not walking the road of genetic engineering, gene therapy approaches and immunotherapy? Our optimism becomes realistic, especially when a scientific rationale is explained by researchers in scientifically solid firms that are specialized in cancer treatment with novel breakthrough methods.  More...

Aimmune Therapeutics: Oral Peanut desensitization Treatment is Promising

  Wednesday, November 11, 2015

Food allergies are bad, significant, dangerous and growing in the U.S. and the rest of the world. More than 30 million people in the United States and Europe have a food allergy, and more than five million people in the United States and Europe have peanut allergy, including more than two million children.  More...

Exeixis Will Begin Reaping the Fruits

  Tuesday, November 10, 2015

 More...

Incyte is A Great Biotech Firm

  Saturday, November 07, 2015

To shareholders who were stupefied with an instigated selloff of Incyte’s (INCY) stock today, we say do not get panicky. Nothing is wrong with Incyte, no bad news was announced with any of the firm’s 12 ongoing clinical trials or with its approved drug Jakafi, which demonstrated progressive growth since it was launched.  So, a clever correct move now would be taking advantage and accumulate INCY.  More...


Recent Postings


Archive


Tags

PTC Therapeutics (PTCT) Agenus (AGEN Exelixis (EXEL) galapagos (GLPG) Human Longevity (HLI) Amgen (AMGN) Sequenom (SQNM) Revlimid (lenolidamide) Cytokinetics (CYTK) IDERA (IDRA) Array Pharmaceuticals (ARRY) SYNTA (SNTA) Dendreon (DNDN) Roche (RHHBY) Biocryst (BCRX) INNOVIVA (INVA) Auspex (ASPX) Editas (EDIT) Anacor (ANAC) Galena (GALE) ZALTRAP™ Zerenex Anadys (ANDS) Trastuzumab-DM1 Gilead (GILD) KERYX (KERX) Intermune (ITMN) ACADIA (ACAD) ISIS (ISIS) KITE (KITE) Sarepta (SRPT) Ariad (ARIA) ARCA (ABIO) Xoma (XOMA) CompuGen (CGEN) Seattle Genetics (SGEN) ARGOS (ARGS) Agenus (AGEN) C4 Therapeutics SERES THERAPEUTICS (MCRB) TOKAI (TKAOI) Ridaforolimus Telaprevir Regeneron (REGN) NANTKWEST (NK) Valeant Pharmaceuticals International (VRX) GlaxoSmithKline (GSK) Idenix (IDIX) Elan (ELN) Micromet (MITI) Vertex (VRTX) RenenxBio (RGNX) Mirati Therapeutics (MRTX) ADVENTRIX (ANX) Jazz Pharmaceuticals (JAZZ) GUARDIAN HEALTH Spike Therapeutics (ONCE) OSI (OSIP) Aimmune Therapeutics (AIMT) Inovio (INO) Human Genome Sciences (HGSI) Illumina (ILMN) Ionis (IONS) Alder Biopharmaceuticals (ALDR) Merck (MRK) Abbott Laboratories (ABT) Intrexon (XON) Genentech Multiple Myeloma Roche (ROCHE) Tysabri AGOS (ARGS) Incyte (INCY) Sangamo (SGMO) Theravance Bio Pharma (TBPH) VANDA (VNDA) Global Cell Therapeutics (GBT) Velcade (bortezomib) JUNO (JUNO) Sanofi-Aventis (SAN) Sanofi (SNA) Pluristem (PSTI) ABBVIE (ABBV) Alnylam (ALNY) Benlysta (belimumab) Theravance (THRX) Bristol-Myers Squibb (BMY) BIOMARIN (BMRN) Biogen Idec (BIIB) SUNESIS PHARMACEUTICALS (SNSS) NEKTAR (NKTR)) Prolor Biotech (PBTH) ImmunoGen (IMGN) Herceptin Dynavax (DVAX) Rapamune AERIE PHARMACEUTICALS Intercept (ICPT) Onyx (ONXX) Prosensa (RNA) HALOZYME (HALO) Vitae Pharmaceuticals (VTAE) Endometrial Cancer REGULUS (RGLS) Sanofi (SNY) Ziofpharm (ZIOP)